Acute myeloid leukemia (AML) is the disease of elderly patients. Therefore, a significant number of patients are not suitable for intensive induction chemotherapy. In this study, it was aimed to retrospectively evaluate patients with AML who were treated Venatoclax-based regimens in our center.

The data of the patients who were treated Venatoclax-based regimens with the diagnosis of AML in the Bozyaka Training and Research Hospital Department of Hematology were scanned retrospectively from their files.

Data of 11 patients in total were reached. The mean age of the patients was 73.9.  8 of 11 patients were follow-up with diagnosis of AML  , 3 patients with MDS RAEB II. Average follow-up time was 13.6 months. 5 patients died during follow-up.  HMA +venatoclax was given to 6 patients  as first-line, 4 patients second-line and 1 patient third-line therapy. Complete response was found in 3 patients, partial response in 1 patient, stable disease in 1 patient, and refractory disease in 1 patient.

Venatoclax is a promising treatment option because it is an oral agent that can be tolerated by elderly patients and improves response rates and survival.